BioLine RX Ltd
TASE:BLRX
BioLine RX Ltd
Net Income (Common)
BioLine RX Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
B
|
BioLine RX Ltd
TASE:BLRX
|
Net Income (Common)
-$60.6m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-14%
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Net Income (Common)
-$7m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Kamada Ltd
NASDAQ:KMDA
|
Net Income (Common)
$12.5m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Net Income (Common)
-$104.3m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Net Income (Common)
-$8.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Net Income (Common)
-₪28.5m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-11%
|
See Also
What is BioLine RX Ltd's Net Income (Common)?
Net Income (Common)
-60.6m
USD
Based on the financial report for Dec 31, 2023, BioLine RX Ltd's Net Income (Common) amounts to -60.6m USD.
What is BioLine RX Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-14%
Over the last year, the Net Income (Common) growth was -143%. The average annual Net Income (Common) growth rates for BioLine RX Ltd have been -26% over the past three years , -21% over the past five years , and -14% over the past ten years .